Publication of a peer-reviewed study in the Journal of the Alzheimer’s Association could mark a milestone for Longeveron

Recent publication of Longeveron is LGVN peer-reviewed study in the Journal of the Alzheimer’s Association is an important step for the company. “Results of its Lomecel-B for Alzheimer’s Disease Phase 1 Trial in Alzheimer’s Disease and Dementia” for Lomecel-B to treat patients with mild Alzheimer’s disease have reached their main objective in the study by demonstrating that it was well tolerated by the patient population.

The development of Lomecel-B by Longeveron will continue. The company announced last quarter a cooperative Alzheimer’s disease research and development agreement with the US Department of Veterans Affairs to add its Miami clinical site to the company’s ongoing Phase 2 trial. The Phase 2a CLEAR MIND trial is designed to study safety and tolerability, as well as cognitive function and biomarkers, after single or multiple infusions of Lomecel-B.

As Longeveron noted in raising awareness about the trial’s success, “The results of this study could have important implications for tackling this devastating disease… [which] an estimated 6.5 million Americans aged sixty-five and older live with it. The company is just one of many companies working to bring new treatments to market, ranging from small companies such as Anvis Bio Inc. ANVS to companies such as Eli Lilly and Co. THERE IS.

This post contains sponsored advertising content. This content is for informational purposes only and is not intended to be investment advice.

Photo by jesse orrico on Unsplash

Jacob L. Thornton